Brief: Basilea Reports New Prevalence Data For EB1 In Glioblastoma And Other Tumor Types

Basilea Pharmaceutica AG, Allschwil

07/06/2021 06:17

June 7 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * BASILEA REPORTS NEW PREVALENCE DATA FOR EB1, A POTENTIAL
RESPONSE-PREDICTIVE BIOMARKER FOR LISAVANBULIN IN GLIOBLASTOMA
AND OTHER TUMOR TYPES, AT ASCO ANNUAL MEETING

Source text for Eikon:  ID:nGNEbC9jyP 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))